Home › Companies › Mirum Pharmaceuticals, Inc. › 2025-2026

Mirum Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

5Ballot items
346Asset managers
2,096Fund votes
June 15, 2026Meeting date

Results at a glance

Meeting of June 15, 2026: 5 items on Mirum Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 3 elected · 2 approved.

Material dissent

Elect Director: Timothy Walbert 70% of votes cast Elected Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Mirum Pharmaceuticals, Inc.

These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Mirum Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 15, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Lon Cardon, Ph.D., FMedSci	39,587,327	--	--	6,827,214	3,614,839	85%	Elected	—
Elect Director: William Fairey	40,266,848	--	--	6,147,693	3,614,839	87%	Elected	—
Elect Director: Timothy Walbert	32,329,718	--	--	14,084,823	3,614,839	70%	Elected	—
2. Ratification of the Selection of Independent Registered Public Accounting Firm	49,993,514	5,674	30,192	--	--	99.9%	Approved	—
3. Advisory Vote on Executive Compensation	44,534,575	1,866,719	13,247	--	3,614,839	96%	Approved	—

Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Mirum Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 346 asset managers that disclosed a Mirum Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Lon Cardon, Ph.D., FMedSci

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD

FOR: 39,587,327WITHHELD: 6,827,214

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSci

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lon Cardon, Ph.D., FMedSci”): 39,587,327 for, 6,827,214 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 18,796,478 for, 2,715,516 withheld, 15 abstained.

FOR

FOR: 18,796,478ABSTAIN: 15WITHHOLD: 2,715,516

Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,996,195	15	15,615	For
Fidelity	3,343,663	0	400	For
JANUS INVESTMENT FUND	2,337,661	0	0	For
BlackRock	1,430,878	0	0	For
MUTUAL FUND SERIES TRUST	1,316,739	0	0	For
State Street	1,018,042	0	1,170	For
T. Rowe Price	935,510	0	0	For
Capital Group	724,415	0	0	For
Charles Schwab	427,375	0	0	For
TIAA	400,747	0	0	For
FRANKLIN STRATEGIC SERIES	377,949	0	0	For
Lord Abbett	0	0	377,552	Withhold
Legg Mason	373,615	0	2,776	For
Federated Hermes	348,028	0	0	For
Loomis Sayles	0	0	259,022	Withhold
Waddell & Reed	0	0	234,817	Withhold
Bridge Builder Trust	130,539	0	80,972	Mixed
Invesco	211,401	0	0	For
Erste Asset Management GmbH	0	0	210,000	Withhold
MFS	0	0	198,836	Withhold
BNY Mellon	156,035	0	1,449	For
RBB FUND, INC.	0	0	156,154	Withhold
Manager Directed Portfolios	151,871	0	0	For
First Trust	0	0	127,079	Withhold
Columbia Threadneedle	121,323	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

2. Elect Director: Timothy Walbert

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD

FOR: 32,329,718WITHHELD: 14,084,823

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy Walbert

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Timothy Walbert”): 32,329,718 for, 14,084,823 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 14,838,879 for, 6,673,098 withheld, 31 abstained.

FORWITHHOLD

FOR: 14,838,879ABSTAIN: 31WITHHOLD: 6,673,098

Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meet” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,994,061	31	17,733	For
Fidelity	3,326,412	0	17,651	For
JANUS INVESTMENT FUND	2,337,661	0	0	For
BlackRock	92,125	0	1,338,753	Mixed
MUTUAL FUND SERIES TRUST	1,316,739	0	0	For
State Street	2,012	0	1,017,200	Withhold
T. Rowe Price	935,510	0	0	For
Capital Group	724,415	0	0	For
Charles Schwab	0	0	427,375	Withhold
TIAA	400,747	0	0	For
FRANKLIN STRATEGIC SERIES	377,949	0	0	For
Lord Abbett	0	0	377,552	Withhold
Legg Mason	373,615	0	2,776	For
Federated Hermes	348,028	0	0	For
Loomis Sayles	0	0	259,022	Withhold
Waddell & Reed	0	0	234,817	Withhold
Bridge Builder Trust	122,500	0	89,011	Mixed
Invesco	0	0	211,401	Withhold
Erste Asset Management GmbH	0	0	210,000	Withhold
MFS	0	0	198,836	Withhold
BNY Mellon	0	0	157,484	Withhold
RBB FUND, INC.	0	0	156,154	Withhold
Manager Directed Portfolios	151,871	0	0	For
First Trust	0	0	127,079	Withhold
Columbia Threadneedle	0	0	121,323	Withhold

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. Elect Director: William Fairey

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 40,266,848WITHHELD: 6,147,693

Details: description as filed, official tally, votes by 107 asset managers

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Fairey”): 40,266,848 for, 6,147,693 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 19,281,381 for, 2,230,614 withheld, 14 abstained.

FOR

FOR: 19,281,381ABSTAIN: 14WITHHOLD: 2,230,614

Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,996,196	14	15,615	For
Fidelity	3,336,129	0	7,934	For
JANUS INVESTMENT FUND	2,337,661	0	0	For
BlackRock	1,338,753	0	92,125	Mixed
MUTUAL FUND SERIES TRUST	1,316,739	0	0	For
State Street	1,018,042	0	1,170	For
T. Rowe Price	935,510	0	0	For
Capital Group	724,415	0	0	For
Charles Schwab	427,375	0	0	For
TIAA	400,747	0	0	For
FRANKLIN STRATEGIC SERIES	377,949	0	0	For
Lord Abbett	0	0	377,552	Withhold
Legg Mason	373,615	0	2,776	For
Federated Hermes	348,028	0	0	For
Loomis Sayles	259,022	0	0	For
Waddell & Reed	0	0	234,817	Withhold
Bridge Builder Trust	211,511	0	0	For
Invesco	211,401	0	0	For
Erste Asset Management GmbH	0	0	210,000	Withhold
MFS	198,836	0	0	For
BNY Mellon	156,035	0	1,449	For
RBB FUND, INC.	0	0	156,154	Withhold
Manager Directed Portfolios	151,871	0	0	For
First Trust	0	0	127,079	Withhold
Columbia Threadneedle	121,323	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

4. 3. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%

FOR: 44,534,575AGAINST: 1,866,719

Details: description as filed, official tally, votes by 346 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 44,534,575 for, 1,866,719 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 105 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,011,822	3	For
Fidelity	3,344,063	0	For
JANUS INVESTMENT FUND	2,337,661	0	For
BlackRock	1,430,878	0	For
MUTUAL FUND SERIES TRUST	1,316,739	0	For
State Street	1,019,212	0	For
T. Rowe Price	935,510	0	For
Capital Group	0	724,415	Against
Charles Schwab	427,375	0	For
TIAA	400,747	0	For
FRANKLIN STRATEGIC SERIES	377,949	0	For
Lord Abbett	377,552	0	For
Legg Mason	376,391	0	For
Federated Hermes	348,028	0	For
Loomis Sayles	259,022	0	For
Waddell & Reed	234,817	0	For
Bridge Builder Trust	211,511	0	For
Invesco	211,401	0	For
MFS	198,836	0	For
BNY Mellon	1,449	156,035	Against
RBB FUND, INC.	156,154	0	For
Manager Directed Portfolios	151,871	0	For
First Trust	127,079	0	For
Columbia Threadneedle	0	121,323	Against
Equitable	120,413	0	For

Fund voting reports, all 105 managers: 20,294,335 for, 1,001,840 against, 4,097 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 267 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	11,472,257	0	For
Fidelity	2,479,063	0	For
T. Rowe Price	1,504,996	0	For
BVF INC/IL	1,259,727	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,210,777	0	For
Novo Holdings A/S	1,125,000	0	For
FRANKLIN ADVISERS INC	790,698	0	For
BlackRock	778,276	0	For
Capital Group	0	724,415	Against
Rock Springs Capital Management LP	701,666	0	For
Wellington	692,613	0	For
Clearbridge Investments, LLC	650,961	0	For
State Street	624,646	0	For
Paradigm Biocapital Advisors LP	560,305	0	For
Polar Capital Holdings Plc	535,592	0	For
RA CAPITAL MANAGEMENT, L.P.	509,686	0	For
Federated Hermes	494,725	0	For
LORD, ABBETT & CO. LLC	484,845	0	For
Loomis Sayles	447,239	0	For
Candriam S.C.A.	434,692	0	For
Nuveen	427,653	0	For
Charles Schwab	427,583	0	For
Vanguard	388,521	0	For
PICTET ASSET MANAGEMENT SA	374,900	0	For
BOONE CAPITAL MANAGEMENT LLC	356,269	0	For

Institutional-manager reports, all 267 managers: 35,730,748 for, 1,585,862 against, 106 abstained, 661 not voted. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 49,993,514AGAINST: 5,674

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 49,993,514 for, 5,674 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 21,507,912 for, 4,097 abstained.

FOR

FOR: 21,507,912ABSTAIN: 4,097

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	4,011,825	For
Fidelity	3,344,063	For
JANUS INVESTMENT FUND	2,337,661	For
BlackRock	1,430,878	For
MUTUAL FUND SERIES TRUST	1,316,739	For
State Street	1,019,212	For
T. Rowe Price	935,510	For
Capital Group	724,415	For
Charles Schwab	427,375	For
TIAA	400,747	For
FRANKLIN STRATEGIC SERIES	377,949	For
Lord Abbett	377,552	For
Legg Mason	376,391	For
Federated Hermes	348,028	For
Loomis Sayles	259,022	For
Waddell & Reed	234,817	For
Bridge Builder Trust	211,511	For
Invesco	211,401	For
Erste Asset Management GmbH	210,000	For
MFS	198,836	For
BNY Mellon	157,484	For
RBB FUND, INC.	156,154	For
Manager Directed Portfolios	151,871	For
First Trust	127,079	For
Columbia Threadneedle	121,323	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

Largest Mirum Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,926,165 shares outstanding at the time of that meeting.

Fund voting reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	6.58%
2	Fidelity	5.49%
3	JANUS INVESTMENT FUND	3.84%
4	BlackRock	2.35%
5	MUTUAL FUND SERIES TRUST	2.16%
6	State Street	1.67%
7	T. Rowe Price	1.54%
8	Capital Group	1.19%
9	Charles Schwab	0.70%
10	TIAA	0.66%

Institutional-manager reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	18.83%
2	Fidelity	4.07%
3	T. Rowe Price	2.47%
4	BVF INC/IL	2.07%
5	GEODE CAPITAL MANAGEMENT, LLC	1.99%
6	Novo Holdings A/S	1.85%
7	FRANKLIN ADVISERS INC	1.30%
8	BlackRock	1.28%
9	Capital Group	1.19%
10	Rock Springs Capital Management LP	1.15%

Reported Mirum Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Mirum Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP Ltd.	9.70%	13G
Patrick Heron	6.74%	DEF14A
James N. Topper	6.61%	13D
BlackRock	6.31%	13F
Frazier Life Sciences IX, L.P.	5.85%	DEF14A
Vanguard Group	4.26%	13F
FMR (Fidelity)	3.23%	13F
State Street	3.19%	13F
Christopher Peetz	2.98%	DEF14A
T. Rowe Price	2.82%	13F

Percentages above are of 60,926,165 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Mirum Pharmaceuticals, Inc.'s shareholder meeting held June 15, 2026, in the 2025-2026 proxy season, 346 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,096 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Mirum Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.